TABLE 1.

Activities of β-lactam–β-lactamase inhibitor antimicrobial agents and comparators against bacterial strains

Species or group (no. of isolates)	Antimicrobial agent	MIC (μg/ml)			% Susceptiblea
		Range	MIC50	MIC90
Achromobacter (100)	Ceftazidime	1 to >32	8	32	71
	Ceftazidime-avibactam	1 to >32	8	32	78
	Ceftolozane-tazobactam	≤0.5 to >32	>32	>32	1
	Meropenem	≤0.5 to >32	1	>32	72
	Meropenem-vaborbactam	≤0.5 to 32	≤0.5	8	86
	Piperacillin-tazobactam	≤2 to >128	≤2	128	87
Burkholderia cepacia complex (150)	Ceftazidime	≤0.5 to >32	4	8	91
	Ceftazidime-avibactam	≤0.5 to >32	4	4	97
	Ceftolozane-tazobactam	≤0.5 to >32	1	8	89
	Meropenem	≤0.5 to >32	2	4	90
	Meropenem-vaborbactam	≤0.5 to >32	1	2	97
	Piperacillin-tazobactam	≤2 to >128	4	64	85
Burkholderia gladioli (50)	Ceftazidime	4 to >32	16	32	20
	Ceftazidime-avibactam	2 to >32	16	16	24
	Ceftolozane-tazobactam	2 to >32	16	32	12
	Meropenem	≤0.5 to 4	1	2	100
	Meropenem-vaborbactam	≤0.5 to 4	1	2	100
	Piperacillin-tazobactam	≤2 to 4	≤2	≤2	100
Stenotrophomonas maltophilia (100)	Ceftazidime	≤0.5 to >32	32	>32	34
	Ceftazidime-avibactam	≤0.5 to >32	16	>32	40
	Ceftolozane-tazobactam	≤0.5 to >32	32	>32	27
	Meropenem	≤0.5 to >32	>32	>32	11
	Meropenem-vaborbactam	≤0.5 to >32	>32	>32	12
	Piperacillin-tazobactam	≤2 to >128	128	>128	18
Pandoraea (20)	Ceftazidime	>32	>32	>32	0
	Ceftazidime-avibactam	>32	>32	>32	0
	Ceftolozane-tazobactam	>32	>32	>32	0
	Meropenem	32 to >32	>32	>32	0
	Meropenem-vaborbactam	32 to >32	>32	>32	0
	Piperacillin-tazobactam	8 to >128	64	>128	5

^aSusceptibility based on CLSI breakpoints established for Pseudomonas aeruginosa as follows: ceftazidime, ≤8 μg/ml; ceftazidime-avibactam, ≤8 μg/ml; ceftolozane-tazobactam, ≤4 μg/ml; meropenem, ≤4 μg/ml; meropenem-vaborbactam, ≤4 μg/ml; piperacillin-tazobactam, ≤16 μg/ml.